Scholar Rock keeps apitegromab FDA decision alive as Europe filing is reset

Scholar Rock (NASDAQ: SRRK) has successfully removed Catalent Indiana LLC, now part of Novo Nordisk, as a commercial fill-finish facility from the U.S. Biologics License Application for apitegromab in spinal muscular atrophy, preserving a potential FDA approval decision by September 30, 2026 despite a manufacturing complication that has disrupted the drug’s European regulatory path. The company said the FDA review is continuing with an alternate fill-finish facility that was already incorporated into the U.S. filing, and commercial vials from that facility are available if apitegromab receives approval. Europe is taking a different route: Scholar Rock withdrew its Marketing Authorisation Application after Catalent Indiana received an Official Action Indicated inspection classification and plans to resubmit with the alternate manufacturer. Japan provides a counterweight to that setback, with the Pharmaceuticals and Medical Devices Agency agreeing that no additional Japanese clinical studies are required for a planned filing by the end of 2026.

The August 21 update turns what could have become a broad regulatory delay into a geographically uneven manufacturing issue. In the United States, the existence of a second fill-finish site has so far insulated the core approval timeline. In Europe, the same manufacturing problem has required a formal withdrawal and resubmission, delaying the path toward a Committee for Medicinal Products for Human Use opinion. For Scholar Rock, the immediate value question therefore remains concentrated on whether the FDA can complete its review using the alternate facility before the September 30 Prescription Drug User Fee Act deadline.

Why did Scholar Rock remove Catalent Indiana from the apitegromab BLA?

The problem originated with an April 2026 FDA inspection of Catalent Indiana’s Bloomington fill-finish operation. Scholar Rock said it received notification on August 7 that the facility had been classified Official Action Indicated, which generally means the regulator identified conditions serious enough to warrant regulatory or administrative action. Apitegromab itself was not described as the cause of the inspection outcome, but because the facility formed part of the manufacturing chain in the BLA, the classification created a regulatory risk around approval. Scholar Rock had already submitted an alternate fill-finish facility as part of the application, providing the company with a second manufacturing route rather than forcing it to construct an entirely new supply strategy after the inspection result.

Under FDA guidance, Scholar Rock has now formally removed Catalent Indiana from the BLA. That matters because manufacturing readiness is evaluated alongside efficacy and safety in biologics approval, and a strong clinical dataset cannot compensate indefinitely for an unacceptable commercial manufacturing site. The company says the alternate facility has undergone successful FDA and European inspections and already has a stock of apitegromab commercial vials available for packaging and labeling if authorization is granted. The September decision date is therefore still achievable, although the FDA retains discretion over whether additional manufacturing information or review time becomes necessary.

Why did Europe require a full apitegromab application withdrawal?

The European application contained Catalent Indiana as the commercial fill-finish site, and the European Medicines Agency had been waiting for greater clarity around the FDA inspection status. Once the Official Action Indicated classification became known, Scholar Rock elected to withdraw the application through the CHMP written procedure that concluded on August 20. It intends to remove Catalent Indiana and resubmit the application using the alternate facility, which management believes represents the most efficient route toward a future CHMP opinion.

Withdrawal does not mean the clinical application has been rejected on efficacy grounds, but it does push Europe behind the United States commercially. Scholar Rock had previously been working toward regulatory decisions across major markets in relatively close sequence, creating the possibility of a coordinated global launch. The European reset makes the U.S. approval outcome more important because an American launch could now begin while European regulators are reviewing a resubmitted manufacturing package. That sequencing increases the commercial importance of successfully executing the alternate U.S. supply chain.

How strong is the Phase 3 evidence behind apitegromab?

Apitegromab is a selective inhibitor of myostatin activation designed to improve skeletal muscle function rather than directly modifying survival motor neuron protein levels. That gives it a different mechanism from established SMA therapies such as nusinersen, risdiplam and gene replacement approaches. Scholar Rock developed the drug as an add-on treatment for patients already receiving an SMN-targeted therapy, meaning its commercial proposition depends on demonstrating additional motor benefit despite modern background treatment.

The Phase 3 SAPPHIRE trial met its primary endpoint. In the main efficacy population of patients aged two to 12, the combined 10 mg/kg and 20 mg/kg apitegromab groups produced a 1.8-point mean difference from placebo on the Hammersmith Functional Motor Scale Expanded at 52 weeks, with a p-value of 0.0192. About 30.4% of apitegromab-treated patients improved by at least three HFMSE points compared with 12.5% on placebo, while 19.6% improved by at least four points compared with 6.3% on placebo. All participants remained on chronic SMN-directed therapy, making the incremental motor-function signal central to the product’s differentiation.

The dataset is not uniformly positive across every individual dose analysis. Scholar Rock reported that the 20 mg/kg group alone showed a 1.4-point mean difference from placebo with a p-value of 0.11, while the prespecified combined-dose analysis met the primary statistical threshold. The broader development program and secondary outcomes supported the regulatory submission, but investors will still need to pay close attention to final labeling, dose selection and how the FDA characterizes the size and consistency of treatment benefit if approval is granted.

Why does Japan improve the global regulatory picture?

Scholar Rock said Japan’s Pharmaceuticals and Medical Devices Agency has agreed that the company does not need to conduct additional clinical studies specifically in Japanese patients before submitting an application. The company is therefore targeting a Japanese New Drug Application by the end of 2026. That conclusion is based on PMDA guidance allowing certain products to rely on global clinical evidence where conditions for filing without dedicated Japanese data are satisfied.

For a small biotechnology company, avoiding another large regional efficacy trial can save considerable time and capital. It also supports Scholar Rock’s ambition to turn apitegromab into a global rare-disease franchise rather than a U.S.-only product. Japan has a sophisticated SMA treatment market and established specialist infrastructure, making the ability to move directly into regulatory review strategically meaningful even as Europe experiences a delay.

Can Scholar Rock finance an apitegromab launch without immediately raising more capital?

Scholar Rock reported cash, cash equivalents and marketable securities of approximately $492 million at June 30, including $63 million of proceeds from its at-the-market equity program. The company has already established a U.S. commercial organization and says that team is active with SMA centers and prescribers in preparation for a potential launch immediately after FDA approval. That balance sheet reduces near-term financing pressure during a period when manufacturing, launch inventory and commercialization expenses could otherwise force a smaller biotechnology company into a poorly timed capital raise.

The company is simultaneously spending on additional apitegromab programs, including the Phase 2 OPAL study in younger children and the Phase 2 FORGE study in facioscapulohumeral muscular dystrophy. It is also developing a high-concentration subcutaneous formulation that could eventually reduce dependence on intravenous administration. Those programs create potential lifecycle value but also consume capital before apitegromab generates any commercial revenue.

How are investors pricing the manufacturing risk in SRRK shares?

Scholar Rock closed at $56.42 on August 21, up 2.1% for the session after trading between $54.98 and $56.42. The stock had ended August 17 at $52.05, putting it up roughly 8.4% over four sessions even as investors absorbed the manufacturing developments. Yahoo Finance showed a year-to-date total return of about 26.9% and a one-year return of roughly 61.7% through August 21, indicating that investors continue to assign substantial probability to a successful apitegromab commercialization.

The valuation now carries a particularly clear binary catalyst. If the FDA accepts the alternate fill-finish setup and approves apitegromab by September 30, Scholar Rock moves rapidly from clinical-stage biotechnology into a commercial launch with a differentiated muscle-directed SMA product. A manufacturing-related delay would be more damaging precisely because management has repeatedly emphasized that the second facility is ready and the remaining U.S. path is intact. Europe has already demonstrated that manufacturing issues can disrupt timing even when clinical evidence remains unchanged.